

BC Cancer ST Program Updates for July 2024

AFFECTED APPLICATION(S)	PowerChart: Oncology/Hematology Regimens and PowerPlans
AFFECTED AREA(S)	BC Cancer VC/Vancouver General Hospital (Oncologists, Oncology Pharmacy, and Oncology Nursing Staff)
NET NEW, OR UPDATE TO EXISTING BUILD	Update to Existing Build


What has Changed?

Any changes released that affect Oncology Regimens and PowerPlans/Cycles for the **BC Cancer Systemic Therapy (ST) Program** will be communicated monthly via Special Bulletin.

These notification changes are important for Nursing staff, Pharmacy, and Providers to be aware of for their patient's care.

For Providers:

- **For PowerPlans that are versioned:** If your patient has already started on a Regimen, when you order the next cycle PowerPlan, a pop-up window will appear to indicate a new version is required.
 - Click **Yes** to accept the new version.
 - **Do not** use the Copy Forward functionality to ensure that the updates apply.



- **IMPORTANT:** Any change from the standard treatment regimen (dose modification, addition of pre-med, etc.) in the previous cycle will need to be manually added to the cycle that is being ordered with the new version (see additional documentation regarding versioning).

Please see this month's changes below:

PowerPlan: MYMPBOR

Cycles/PowerPlans: All associated treatment PowerPlans

Changes:

In the Prescriptions Phase:

- Updated special instructions for dexamethasone to include Day 29: 'Take in the morning on Days 1, 8, 15, 22, **29** of each cycle.

ONCP MY MYMPBOR Cycles 1 and 2 - Cycle 1, Prescriptions (Future Pending)	
For melphalan dosing, melphalan and predniSONE are to be given in combination for Days 1 to 4	
<input type="checkbox"/> melphalan	9 mg/m ² , PO, as directed, Take daily on days 1-4 of each cycle, drug form: tab, dispense qty: 35 day Round dose to nearest 2 mg. Prescription is part of a combined IV/PO protocol. Dispense quantity = 1 cycle
<input type="checkbox"/> predniSONE	60 mg/m ² , PO, as directed, Take daily on days 1-4 of each cycle, drug form: tab, dispense qty: 35 day Round to nearest 25 mg. Prescription is part of a combined IV/PO protocol. Dispense quantity = 1 cycle
If substituting cyclophosphamide for melphalan, then steroid dosing has to be modified accordingly	
<input type="checkbox"/> cyclophosphamide	Select an order sentence
<input type="checkbox"/> dexamethasone	Select an order sentence
<input type="checkbox"/> predniSONE	20 mg, PO, as directed, Take in the morning on Days 1, 8, 15, 22, 29 of each cycle, drug form: tab, dispense qty: 35 day 40 mg, PO, as directed, Take in the morning on Days 1, 8, 15, 22, 29 of each cycle, drug form: tab, dispense qty: 35 day

In the Prescriptions (Inpatient Use Only) Phase:

- Updated order comments of dexamethasone to include Day 29: Days 1, 8, 15, 22, **29**.
- Updated order duration of dexamethasone to be 5 doses or times.

ONCP MY MYMPBOR Cycles 1 and 2 - Cycle 1, Prescriptions (Inpatient Use Only) (Future Pending)	
For melphalan dosing, melphalan and predniSONE are to be given in combination for Days 1 to 4	
<input type="checkbox"/> melphalan	9 mg/m ² , PO, qdaily, order duration: 4 doses or times Round to nearest 2 mg. Medication is part of a combined IV/PO protocol. Days
<input type="checkbox"/> predniSONE	60 mg/m ² , PO, qdaily with breakfast, order duration: 4 doses or times, drug form: tab Round to nearest 25 mg. Medication is part of a combined IV/PO protocol. Days
If substituting cyclophosphamide for melphalan:	
<input type="checkbox"/> cyclophosphamide	Select an order sentence
<input type="checkbox"/> predniSONE	100 mg, PO, q2day interval, order duration: 18 doses or times, drug form: tab Medication is part of a combined IV/PO protocol
<input type="checkbox"/> dexamethasone	20 mg, PO, qweek oncology, order duration: 5 doses or times, drug form: tab Medication is part of a combined IV/PO protocol. Days 1, 8, 15, 22, 29

Versioning: Yes

Jira: CST-264283

PowerPlan: LYALEM

Cycles/PowerPlans: Regimen and Pretreatment Plan

Changes:

Added the following note to the top of the Pretreatment Plan, top of the regimen and in the regimen description:

Alemtuzumab ceased to be commercially available in 2012. Prescribers must apply for a patient-specific supply of alemtuzumab at least 1 week prior to the scheduled treatment through the Clinigen MabCampath Distribution Program (CDP) by email at medicineaccess@clinigengroup.com

ONC LY LALEM (Pending)

▼ Hide additional details

Regimen description: Treatment with Subcutaneous or Intravenous Alemtuzumab for Fludarabine-Refractory B-Chronic Lymphocytic Leukemia (B-CLL) or with Intravenous Alemtuzumab for Previously Untreated T-Prolymphocytic Leukemia (T-PLL)
Alemtuzumab ceased to be commercially available in 2012. Prescribers must apply for a patient-specific supply of alemtuzumab at least 1 week prior to the scheduled treatment through the Clinigen MabCampath Distribution Program (CDP) by email at medicineaccess@clinigen.com

+ Add Document Response View Responses

Alemtuzumab ceased to be commercially available in 2012. Prescribers must apply for a patient-specific supply of alemtuzumab at least 1 week prior to the scheduled treatment through the Clinigen MabCampath Distribution Program (CDP) by email at medicineaccess@clinigen.com

ONC LY LALEM Pretreatment Plan *Est. Start Date: **/**/**

Versioning: Yes

Jira: CST-263432

PowerPlan: GUEVER

Cycles/PowerPlans: All associated PowerPlans

Changes:

In the Pretreatment Plan:

- Replaced Phosphorus Level with Phosphate Level.
- Added Albumin Level and INR.

ONC GU GUEVER Pretreatment Plan, Baseline Labs (Day 1) (Future Pending) *Est

	Component	Fut
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Creatinine Level Blood, once, Order for future visit	
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Urea Blood, once, Order for future visit	
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Glucose Random Blood, once, Order for future visit	
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Calcium Level Blood, once, Order for future visit	
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Phosphate Level Blood, once, Order for future visit	
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Alanine Aminotransferase Blood, once, Order for future visit	
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Lactate Dehydrogenase Blood, once, Order for future visit	
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Bilirubin Total Blood, once, Order for future visit	
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Albumin Level Blood, once, Order for future visit	
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> INR Blood, once, Order for future visit	

In the Treatment Plan:

- Added INR, Magnesium level, Calcium Level, Phosphate Level, HbA1c, Creatinine Kinase, Urinalysis Macroscopic (dipstick), Protein Urine 24 Hour

Component	Day	Future P
<input checked="" type="checkbox"/> CBC and Differential Blood, once, Order for future visit		Plans
<input checked="" type="checkbox"/> If clinically indicated:		
<input checked="" type="checkbox"/> Protein Level (Total Protein Level) Blood, once, Order for future visit		
<input checked="" type="checkbox"/> Albumin Level Blood, once, Order for future visit		
<input checked="" type="checkbox"/> Bilirubin Total Blood, once, Order for future visit		
<input checked="" type="checkbox"/> INR Blood, once, Order for future visit		
<input checked="" type="checkbox"/> Gamma Glutamyl Transferase Blood, once, Order for future visit		
<input checked="" type="checkbox"/> Alkaline Phosphatase Blood, once, Order for future visit		
<input checked="" type="checkbox"/> Lactate Dehydrogenase Blood, once, Order for future visit		
<input checked="" type="checkbox"/> Alanine Aminotransferase Blood, once, Order for future visit		
<input checked="" type="checkbox"/> Urea Blood, once, Order for future visit		
<input checked="" type="checkbox"/> Creatinine Level Blood, once, Order for future visit		
<input checked="" type="checkbox"/> Sodium and Potassium Panel (Electrolytes Panel Outpat... Blood, once, Order for future visit		
<input checked="" type="checkbox"/> Magnesium Level Blood, once, Order for future visit		
<input checked="" type="checkbox"/> Calcium Level Blood, once, Order for future visit		
<input checked="" type="checkbox"/> Phosphate Level Blood, once, Order for future visit		
<input checked="" type="checkbox"/> Glucose Random Blood, once, Order for future visit		
<input checked="" type="checkbox"/> Hemoglobin A1C (HbA1C) Blood, once, Order for future visit		
<input checked="" type="checkbox"/> Cholesterol Level Blood, once, Order for future visit		
<input checked="" type="checkbox"/> Triglyceride Blood, once, Order for future visit		
<input checked="" type="checkbox"/> Creatine Kinase Blood, once, Order for future visit		
<input checked="" type="checkbox"/> Urinalysis Macroscopic (dipstick) Urine, once, Order for future visit		
<input checked="" type="checkbox"/> If laboratory urinalysis for protein is greater than or equal to 1 g/L, then a 24 hr urine for total protein must be done within 3 days prior to the next cycle.		
<input checked="" type="checkbox"/> Protein Urine 24 Hour Urine, once, Order for future visit		
<input checked="" type="checkbox"/> 'Collection Information Urine 24 Hour' and 'Creatinine Urine 24 Hour' are required tests for 24 hour urine tests		
<input checked="" type="checkbox"/> Collection Information Urine 24 Hour Urine, once, Order for future visit		
<input checked="" type="checkbox"/> Creatinine Urine 24 Hour Urine, once, Order for future visit		

Versioning: Yes

Jira: CST-266983

PowerPlan: ULYVENETO, LYVENETOR, LYVENOB

Cycles/PowerPlans: All associated PowerPlans

Changes:

For LYVENOB Cycle 1 PowerPlan:

- Removed Prescriptions and Prescriptions (Inpatient Use Only) Phases

ONCP LY LYVENOB Cycle 1

Enter Cycle

Select Visit and Start Time

This Visit
 Future Inpatient Visit
 Future Outpatient Visit

Estimated Start Date of Chemotherapy (Day 1 to 2, 8, 15)

In Day(s)
 In Week(s)
 In Month(s)

Est. start 13-Jun-2024 0800 PDT

Confirm Phase Action

Phase	Start Date/Time	Action
Chemotherapy (Day 1 to 2, 8, 15)	*Est. 13-Jun-2024 08:00 PDT	Order for future visit
Labs (Day 2, 22)	*Est. 13-Jun-2024 08:00 PDT	Order for future visit
Scheduling	13-Jun-2024 08:00 PDT	Order now

For **ONCP LY LYVENETOR Low/Moderate TLS Risk Ramp-Up Weeks 1 to 5 (PO)** and
ONCP LY ULYVENETO Low/Moderate TLS Risk Ramp-Up Weeks 1 to 5 (PO)

- Removed Allopurinol order.
- Adjusted yellow allopurinol note to: Ensure patient starts allopurinol at least 72 hours prior to first dose of venetoclax.
- Added new yellow note: Advise patient to drink 1.5 to 2 litres of fluid (8 glasses everyday for the first 6 weeks, starting 2 days before taking the first dose of venetoclax).

Component	Status	Dose ...	Details
ONCP LY LYVENETOR Low/Moderate TLS Risk Ramp-Up Weeks 1 to 5 (PO), Prescriptions (Future Pending)			
Link to Protocol: Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Using Venetoclax and Rituximab			
Revised: 1 Aug 2020			
Start date of dose ramp up must be on a Thursday			
Pre-Chemo Metrics			
May proceed with doses as written if lab work is within 72 hours of venetoclax initiation			
Neutrophils Greater Than or Equal to $1.0 \times 10^9/L$			
Platelet Count Greater Than or Equal to $30 \times 10^9/L$			
Bilirubin Less Than or Equal to 3 x ULN			
Tumour Lysis Prophylaxis			
Ensure patient starts allopurinol at least 72 hours prior to first dose of venetoclax			
Advise patient to drink 1.5 to 2 litres of fluid (8 glasses everyday for the first 6 weeks, starting 2 days before taking the first dose of venetoclax)			
Treatment Regimen			

In the Pretreatment Plan:

- Added HBsAg, HBcoreAb, and HBsAb (if not already there).
- Updated yellow note to: If HBsAg or HBcoreAb positive, follow hepatitis B prophylaxis as per SCHBV protocol.

Component
<input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Bilirubin Total Blood, once, Order for future visit Baseline labs to be done within 72 hours before first treatment
<input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Alanine Aminotransferase Blood, once, Order for future visit Baseline labs to be done within 72 hours before first treatment
<input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Lactate Dehydrogenase Blood, once, Order for future visit Baseline labs to be done within 72 hours before first treatment
<input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Albumin Level Blood, once, Order for future visit Baseline labs to be done within 72 hours before first treatment
<input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Hepatitis B Core Antibody Total BCCDC Blood, once, Order for future visit Baseline labs to be done within 72 hours before first treatment
<input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Hepatitis B Surface Antigen BCCDC Blood, once, Order for future visit Baseline labs to be done within 72 hours before first treatment
<input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Hepatitis B Surface Antibody BCCDC Blood, once, Order for future visit Baseline labs to be done within 72 hours before first treatment
<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> If HBsAg or HBcoreAb positive, follow hepatitis B prophylaxis as per SCHBV protocol

For the following PowerPlans:

- ONCP LY ULYVENETO High TLS Risk Ramp-Up Weeks 3 to 5 (PO)
- ONCP LY ULYVENETO Low/Moderate TLS Risk Ramp-Up Weeks 1 to 5 (PO)
- ONCP LY ULYVENETO Post Ramp-Up (PO)
- ONCP LY LYVENETOR High TLS Risk Ramp-Up Weeks 3 to 5 (PO)
- ONCP LY LYVENETOR Low/Moderate TLS Risk Ramp-Up Weeks 1 to 5 (PO)
- ONCP LY LYVENETOR Post Ramp-Up Cycle 1
- ONCP LY LYVENETOR Post Ramp-Up Cycles 2 to 6
- ONCP LY LYVENOB Cycle 1
- ONCP LY LYVENOB Cycle 2 Low/Moderate TLS Risk Ramp-Up Weeks 1 to 5
- ONCP LY LYVENOB Low/Moderate TLS Risk Ramp-Up Cycle 2 Venetoclax Prescription and Lab Monitoring

ONCP LY LYVENOB Post Ramp-up Cycles 3 to 6
 ONCP LY LYVENOB Post Ramp-up Cycles 7+ (PO)

- Added yellow note to Labs Phase: If clinically indicated, every 3 months:
- Added optional HBV viral load and HBsAg.

ONCP LY ULYVENETO High TLS Risk Ramp-Up Weeks 3 to 5 (PO), Labs (Day)

Component
<input checked="" type="checkbox"/> Creatinine Level Blood, once, Order for future visit Week 3 Day 1 at 12 noon Week 3 Day 2 at 8 am Week 3 Day ...
<input checked="" type="checkbox"/> Lactate Dehydrogenase Blood, once, Order for future visit Week 3 Day 1 at 12 noon Week 3 Day 2 at 8 am Week 3 Day ...
<input checked="" type="checkbox"/> Albumin Level Blood, once, Order for future visit Week 3 Day 1 at 12 noon Week 3 Day 2 at 8 am Week 3 Day ...
<input checked="" type="checkbox"/> Prior to week 6 doctor's visit:
<input checked="" type="checkbox"/> CBC and Differential Blood, once, Order for future visit
<input checked="" type="checkbox"/> Creatinine Level Blood, once, Order for future visit
<input checked="" type="checkbox"/> Bilirubin Total Blood, once, Order for future visit
<input checked="" type="checkbox"/> Alanine Aminotransferase Blood, once, Order for future visit
<input checked="" type="checkbox"/> If clinically indicated, every 3 months:
<input type="checkbox"/> Hepatitis B Surface Antibody BCCDC Blood, once, Order for future visit
<input type="checkbox"/> Hepatitis B Viral Load (Rx monitoring) (HBV Viral Load) Blood, once, Order for future visit

For ONCP LY ULYVENETO High TLS Risk Ramp-Up Prescriptions Weeks 1 to 5 (PO)

- Removed Allopurinol order.
- Added new yellow note: Ensure patient starts allopurinol at least 72 hours prior to first dose of venetoclax.
- Added new yellow note: Advise patient to drink 1.5 to 2 litres of fluid (8 glasses) everyday for the first 6 weeks, starting 2 days before taking the first dose of venetoclax.

ONCP LY ULYVENETO High TLS Risk Ramp-Up Prescriptions Weeks 1 to 5 (PO), Prescriptions (Future Pending)

<input checked="" type="checkbox"/> Link to Protocol: Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Using Venetoclax
<input checked="" type="checkbox"/> Preferred start day of venetoclax dose ramp up to be on a Thursday
<input checked="" type="checkbox"/> Treatment Regimen
<input checked="" type="checkbox"/> Ensure patient starts allopurinol at least 72 hours prior to first dose of venetoclax
<input checked="" type="checkbox"/> Advise patient to drink 1.5 to 2 litres of fluid (8 glasses) everyday for the first 6 weeks, starting 2 days before taking the first dose of venetoclax

Versioning: Yes

Jira: CST-267168

PowerPlan: LYOBEND

Cycles/PowerPlans: All associated PowerPlans and Regimen

Changes:

Updating LYOBEND protocol to LYBENDO

ONC LY LYBENDO
ONCP LY LYBENDO Cycle 1
ONCP LY LYBENDO Cycles 2 to 6
ONCP LY LYBENDO Cycles 7 to 18
ONCP LY LYBENDO Pretreatment Plan

In the Pretreatment Plan:

- Updated HBsAg note to: If HBsAg or HBcoreAb positive, start hepatitis B prophylaxis as per current guidelines.

Component
<input checked="" type="checkbox"/> CBC and Differential Blood, once, Order for future visit
<input checked="" type="checkbox"/> Creatinine Level Blood, once, Order for future visit
<input checked="" type="checkbox"/> Alanine Aminotransferase Blood, once, Order for future visit
<input checked="" type="checkbox"/> Bilirubin Total Blood, once, Order for future visit
<input checked="" type="checkbox"/> Hepatitis B Core Antibody Total BCCDC Blood, once, Order for future visit
<input checked="" type="checkbox"/> Hepatitis B Surface Antigen BCCDC Blood, once, Order for future visit
<input checked="" type="checkbox"/> Hepatitis B Surface Antibody BCCDC Blood, once, Order for future visit
<input checked="" type="checkbox"/> If HBsAg or HBcoreAb positive, start hepatitis B prophylaxis as per current guidelines

In the Treatment Plan:

- ANC parameter changed to 0.8×10^9

Component
Link to Protocol: Treatment of rituximab-refractory Follicular Lymphoma (FL) with obinutuzumab in combination with Bendamustine
Revised: 1 June 2022
Pre-Chemo Metrics
May proceed with treatment on Day 1 if:
Neutrophils Greater Than or Equal to $0.8 \times 10^9/L$ within 96 hours
Platelet Count Greater Than or Equal to $80 \times 10^9/L$ within 96 hours

Versioning: Yes


Jira: CST- 266434

PowerPlan: MYCARLD and MYCARDEX

Cycles/PowerPlans: All associated treatment PowerPlans

Changes:

Update yellow note in Pre-Medications section to say: Optional, if steroid is not given as part of the treatment regimen and if concerns regarding infusion reactions.



Versioning: Yes

Jira: CST-266258

PowerPlan: GIFFIRB, GICIRB, GIFFOXB, GICOXB, GIAVCAPB, GIATZB, GIA, GILEN, GIREGO, GISORAF, UGICABO, GIAVCETIR, GIAVPANI, GIFFIRPAN, GIFFOXPAN, UGIAVPANEN, GIAJNIV, GIGAVCOXN, GIGAVCOXP, GIGAVFFOXN, GIGAVFFOXP, UGIAVPEM, UGIAVPEM6, GIAVCAP, GICAPOX, GIGFOLFIRI, GIPAVFFOX, GIGAVCOXT, GIGAVFFOXT, GIGAVFFOX, GIGAVCOX, GIFOLFIRI, GIAVDOC, GIFUC, GIGAVCCT, GIGAVCFT, GIGAVRAMT, GIGAVTR, GIGAVTRFT, GIEFFOXRT, GIENACTRT, GIGAJCOX, GIGAJCPRT, GIGAJFFOX, GIGFLODOC, GIGECC, GIBAJCAP, GIFIRINOX, GIPAJFIROX, GIPAJGCAP, GIPAJGEM, GIPAVFFIRI, GIPGEM, GIPGEMABR

Cycles/PowerPlans: All associated treatment PowerPlans

Changes:

GI Optimization Part 1. Updated labs to be standard across various disease sites and Chemotherapy treatments.

Versioning: Yes

Jira: CST-265524, CST-264955, CST-264951, CST-264946, CST-264942, CST-265454, CST-265509, CST-265521

Net New Protocols

- ONC New Order Set- GUOTEVER
- ONC New Order Set- LYCHOPO
- ONC New Order Set- LYCVPO
- ONC New Order Set- LYGDPO

- ONC New Order Set- LYTEM
- ONC New Order Set- ULYMOGA

Jira: CST-266668, CST-265658, CST-265672, CST-265673, CST-263280, CST-265117

Jira Ticket #	CST-267168, CST-266983, CST-266434, CST-266258, CST-265524, CST-265521, CST-265509, CST-265454, CST-264955, CST-264951, CST-264946, CST-264942, CST-264283, CST-263432, CST-266668, CST-265658, CST-265672, CST-265673, CST-263280, CST-265117
How-to questions?	http://cstcernerhelp.healthcarebc.ca/
Need further support?	CST Phone Support: 1-844-214-7444